We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microneedle Skin Patch Enables Cancer Biomarker Sampling for Single-Molecule Measurement

By LabMedica International staff writers
Posted on 18 Sep 2023
Print article
Image: Biomarker molecules can be sampled from melanoma lesions using microneedles (Photo courtesy of Wyss Institute)
Image: Biomarker molecules can be sampled from melanoma lesions using microneedles (Photo courtesy of Wyss Institute)

Patients suffering from melanoma, a severe form of skin cancer where cells that produce pigment grow uncontrollably, have mixed results with current immunotherapies. Over half of these patients do not respond to the available immunotherapy medications, and of those who initially do, many later develop resistance. Therefore, medical professionals need tools to identify which patients are likely to respond positively to the treatment from the outset and which ones will continue or stop responding. Given that skin tumors in melanoma patients are easily accessible, applying immunotherapies directly to the affected area, rather than infusing them through the bloodstream, could be more effective. Moreover, observing how the immune system responds to the treatment directly at the tumor location could lead to more personalized care for patients through continuous and accurate monitoring of various indicators that signal effective immune cell activation and the desired inflammatory response.

Now, a research team including scientists at the Wyss Institute at Harvard University (Boston, MA, USA) has developed an innovative technique that combines a minimally invasive, painless microneedle platform with an ultra-sensitive, single-molecule detection method known as Simoa. These microneedles can absorb fluid that contains biomarkers from deeper skin layers, while the Simoa technology can recognize these often elusive but crucial biomarkers with greater sensitivity than traditional methods. As a proof of concept, the researchers tested their approach in a mouse model of melanoma, treating the cancerous growths with a new kind of therapy. This novel treatment employs focused ultrasound to generate heat and instantly kill tumor cells at the lesion site, and it is paired with a specially designed nanoparticle that activates an inflammation-causing protein known as the stimulator of interferon genes (STING).

The team developed four different Simoa assays to detect molecules whose expression is activated by STING: interferon-b (IFN-b), MCP-1 and KC, which draw immune cells towards the tumors, as well as the broad inflammation marker, interleukin-6 (IL-6). This allowed the researchers to detect these biomarkers in fluid samples collected by the microneedles with sensitivities 100 to 1000 times greater than conventional tests. Importantly, these measurements were in line with other Simoa tests of the same biomarkers in blood samples. The study findings are reported in Advanced Functional Materials.

“Rapid readout of the responses to melanoma therapy using microneedles may enable effective drug screening and patient stratification to maximize therapeutic benefits,” said Wyss Associate Faculty member Natalie Artzi, Ph.D., who led the study.

“The Artzi lab’s remarkable microneedle technology containing engineered nanostructures, in principle, enables both, drug delivery and microsampling – a completely new concept for a theranostic, which provides an ideal, non-invasive and comprehensive solution to melanoma treatment,” said Wyss Core Faculty member David Walt, Ph.D., who had previously developed the Simoa technology, which has ultrasensitive biomarker detection abilities.

Related Links:
Wyss Institute at Harvard University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.